Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanzi Huangshi No.2 Pill
- Development stage
- Unknown
- Lead developer
- Shanghai Municipal Hospital of Traditional Chinese Medicine
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sanzi Huangshi No.2 Pill (SHP) is an arsenic-containing Traditional Chinese Medicine (TCM) compound formulation developed by the Shanghai Municipal Hospital of Traditional Chinese Medicine and Shanghai University of Traditional Chinese Medicine. It is primarily indicated for the treatment of myelodysplastic syndrome (MDS), particularly lower-risk MDS. The formula contains arsenic-based active ingredients, which are characteristic of certain TCM treatments for hematological malignancies. SHP is thought to modulate hematopoietic pathways and induce apoptosis or differentiation in dysplastic cells. It has been evaluated in clinical trials as an adjuvant therapy in combination with thalidomide to improve outcomes in MDS patients.
- Other names
- Sanzi-huangshi pillSanzi Huangshi No. 2
02
Targets
Neuroblastoma RAS viral oncogene homolog (NRAS)–Mitogen-activated protein kinase kinase (MEK)–Extracellular signal-regulated kinase (ERK) signaling axis
Beyond the preview
Go deeper on Sanzi Huangshi No.2 Pill.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sanzi Huangshi No.2 Pill.